Non-ribosomal peptide synthetases, ATP-grasp ligases, α-amino acid ester acyltransferases, β-lactam acylases, and cyanophycinases each offer a distinct route to short oligopeptides and peptide-based pharmaceuticals such as 6-aminopenicillanic acid 6-APA and β-Asp-Arg. This article compares their…
Five enzyme families can produce short oligopeptides and peptide-based pharmaceuticals, and they divide into two mechanistic groups. Non-ribosomal peptide synthetases NRPSs and ATP-grasp ligases use ATP to activate a carboxylate before forming the amide bond. α-Amino acid ester acyltransferases AETs , β-lactam acylases , and cyanophycinases need no ATP, because they couple amide bond formation to the energy already stored in an ester, a penicillin, or a storage polymer. The endpoints are concrete: β-lactam acylases generate 6-aminopenicillanic acid 6-APA for semi-synthetic antibiotics, and cyanophycinases release the dipeptide β-Asp-Arg from cyanophycin. Short oligopeptides, from dipeptides up to roughly a dozen residues, sit between single amino acids and folded proteins, and their pharmaceutical value lies in antibiotics, hormones, and nutritional supplements.
The common problem is thermodynamic. An amide bond between a free carboxylic acid and an amine does not form spontaneously in water, so every enzyme family must pay for the bond. NRPSs and ATP-grasp ligases pay with ATP. AETs pay with the energy of an activated ester. β-Lactam acylases and cyanophycinases rearrange or break an existing amide bond, releasing a product that is either a new antibiotic or a preformed dipeptide. The payment method determines what each family can make and at what cost.
Wang and colleagues set out this comparison in a 2019 Biomolecules review, "Strategy for the biosynthesis of short oligopeptides: Green and sustainable chemistry" 2019, 9 11 : 733 . The evidence base the review draws on is uneven. Some families rest on decades of industrial use and high-resolution structures. Others rest on a single strain report with no sequence and no structure. The summary below follows the same order and keeps the two apart.
| Enzyme family | ATP required | Activation chemistry | Representative product |
|---|---|---|---|
| NRPS | Yes | Aminoacyl-AMP in adenylation domain | Penicillin, bleomycin, cyclosporine |
| ATP-grasp ligase | Yes | Enzyme-bound acylphosphate | Glycinamide ribonucleotide, D-Ala-D-Ala |
| α-Amino acid ester acyltransferase | No | Transfer from activated ester | Short oligopeptides |
| β-Lactam acylase | No | Cleavage of penicillin amide | 6-APA |
| Cyanophycinase | No | Cleavage of isopeptide polymer | β-Asp-Arg |
NRPSs are multidomain enzymes in bacteria and fungi that assemble peptides without an mRNA template. The domain architecture is modular, and each module adds one residue in a defined order. The crystal structure of a typical NRPS, PDB ID: 2VSQ, shows the four domains that carry out the cycle. The adenylation A domain selects the amino acid and activates it as an aminoacyl adenylate. The peptidyl carrier protein PCP domain holds the activated residue and the growing chain on a phosphopantetheine arm. The condensation C domain forms the amide bond between the chain and the incoming residue. The thioesterase Te domain releases the finished peptide.
The products justify the clinical interest. The same enzymatic logic yields penicillin, the anticancer agent bleomycin, and the immunosuppressant cyclosporine, and the family produces a wide array of structurally diverse, therapeutically important peptides. The A domain sets the specificity, and the order of modules is what allows the system to be reorganized. The adenylation reaction is one of two activation strategies found in NRP-synthesizing biocatalysts. ATP-dependent enzymes such as tRNA-dependent ligases activate substrates through aminoacyl adenosine monophosphate. ATP-independent enzymes such as transacylases use aminoacyl phosphate. The distinction is practical: ATP-independent systems can run without an energy regeneration mix.
NRPSs are powerful but heavy. Each module is a large protein, and repurposing the system to make a new short peptide requires solving domain boundaries and adapter compatibility. Changing the A domain specificity and recombining whole modules are the two standard engineering routes, and both have produced new peptides, yet neither is fast enough to make NRPSs the default tool for one-off short peptide synthesis. For dedicated production of one defined peptide, the modular design is an advantage. For flexible small-scale synthesis of many sequences, it is a liability.
ATP-grasp enzymes are ATP-dependent carboxylate-amine ligases. They activate the carboxylic acid as an acylphosphate . The carboxylate attacks the γ-phosphate of ATP, and the resulting acylphosphate, which remains enzyme-bound, is then attacked by the amine of the second substrate, displacing phosphate and forming the amide bond. The chemistry is distinct from the aminoacyl-AMP intermediate of the NRPS A domain, and it requires no free activated ester. The family is named for the grasp-like fold that encloses the ATP. Members include biotin carboxylase , the D-alanyl-D-alanine ligase Ddl , and glutathione synthetase , and the reaction type appears in de novo purine biosynthesis.
The structural template is glycinamide ribonucleotide synthetase , PDB ID: 2IP4. It shows the three conserved domains and the nonclassical ATP-binding fold that encloses the ATP molecule. Most family members require an Mg2+ ion coordinated by the ATP in the active site. The acylphosphate is buried inside the enzyme, shielded from bulk water until the amine substrate arrives, which is why the reactive intermediate survives long enough to form a peptide bond.
The mechanism is among the best understood of the five families. For peptide chemistry, ATP-grasp ligases are useful for specific single-bond formations, and the named members are highly specific. Ddl builds the D-Ala-D-Ala dipeptide of bacterial cell walls, a product that is itself the binding target of the glycopeptide antibiotic vancomycin, which is why the enzyme has been studied so thoroughly. Glutathione synthetase adds glycine to a preformed dipeptide. That specificity is valuable where one defined amide bond is the goal, and limiting where a varied peptide sequence is the target.
The most direct ATP-free demonstration of oligopeptide synthesis from unprotected amino acids was reported by Kenzo and colleagues using Empedobacter brevis ATCC 14234 . The strain produced short oligopeptides in high yield, and the responsible enzyme was identified as a carboxypeptidase Y . The report is best read as a proof of principle. The catalyst was described without its amino acid sequence, its coding gene sequence, or its 3D structure, so the enzyme cannot yet be reproduced recombinantly or engineered from a structural model. High yield is the claim; the catalyst is not fully defined, and that combination is exactly the situation in which a process development program should demand a sequence confirmation step.
A parallel line of work by Isao Abe and colleagues cloned and expressed α-amino acid ester acyltransferases from E. brevis strains. The two AETs are 35% and 36% identical in amino acid sequence to the α-amino acid ester hydrolase from Acetobacter pasteurianus. They are relatives of that enzyme, not close homologs. Thirty-five to 36 percent identity sits near the lower boundary of confident homology by sequence alone, so whether the AETs share the hydrolase fold cannot be settled without a structure. AETs display dual dipeptidyl peptidase and transferase activities and are highly specific for both acyl donors and nucleophiles.
The dual activity describes one acylation step with two possible fates. The enzyme removes a dipeptide unit from an acyl donor, and the unit is delivered either to water, which is hydrolysis, or to an amine nucleophile such as an amino acid, which extends the peptide chain. The strict specificity for both partners keeps side reactions low, and it restricts the substrates the enzyme will accept. Two facts block further development. No 3D structure of an AET has been reported, and no detailed reaction mechanism has been established. The catalytic residues are unidentified, and engineering for broader substrate scope is therefore empirical.
β-Lactam acylases are the enzyme family with the clearest industrial record. Three types are studied for β-lactam biosynthesis: penicillin acylase PA , glutaryl acylase GA , and β-amino acid ester hydrolase AEH . Penicillin acylase dominates. It is produced by a variety of microorganisms and is categorized into two types based on substrate specificity, one acting preferentially on the phenylacetyl side chain of penicillin G and the other on the phenoxyacetyl side chain of penicillin V. The enzyme cleaves the amide bond of the penicillin, releasing 6-aminopenicillanic acid 6-APA , the active pharmaceutical intermediate from which all semi-synthetic penicillins are made.
| Enzyme | Substrate | Industrial role |
|---|---|---|
| Penicillin acylase PA | Penicillin G and V | 6-APA production; semi-synthetic antibiotics |
| Glutaryl acylase GA | Glutaryl side chains | Cephalosporin intermediate processing |
| β-Amino acid ester hydrolase AEH | α-Amino acid esters | Peptide and antibiotic coupling |
The three enzymes cover different parts of the β-lactam value chain. Glutaryl acylase removes glutaryl side chains from cephalosporin intermediates. AEH acts on α-amino acid esters and can transfer their acyl groups onto β-lactam nuclei, which is why it is studied alongside the acylases rather than only as a peptide-forming enzyme. Penicillin acylase remains the industrial anchor. Under controlled conditions the acylase reaction can be driven toward synthesis: the enzyme transfers an activated side-chain donor onto 6-APA, forming a new amide bond and a semi-synthetic antibiotic. This kinetically controlled route is the basis of industrial enzymatic acylation, producing drugs such as ampicillin and amoxicillin. Enzymatic synthesis of β-lactams is framed as an environmentally friendly and cost-effective alternative to chemical synthesis, and it is increasingly applied in the pharmaceutical industry for penicillins, cephalosporins, and thiamycins.
Penicillin acylases extend beyond β-lactams. The same enzymes are applied to peptide synthesis, resolution of racemic mixtures, and production of achiral and chiral pharmaceutical intermediates, and they are a candidate platform for developing novel drugs. The breadth is real, but the industrial anchor remains 6-APA.
The green and sustainable framing of enzymatic β-lactam synthesis rests on a comparison with chemical routes that need activated intermediates, organic solvents, and cryogenic conditions. Enzyme routes run in water at moderate temperature and pH, and they skip the protection and deprotection steps of chemical peptide synthesis. Those are real process advantages. They do not change the fundamental feature of each family: specificity. The same property that keeps side products low is the property that limits substrate scope.
Cyanophycin granule polypeptide CGP is an intracellular storage polymer in most cyanobacteria. It contains equimolar arginine and aspartic acid, and its connectivity is unusual. Each arginine is linked through its α-amino group to the β-carboxyl group of an aspartic acid. The polymer is therefore a polyaspartate chain with arginine isopeptide side chains, and it is resistant to proteases that attack α-peptide bonds. CGP is unusual among storage polymers in having a fixed composition, which means the released product is a single defined dipeptide rather than a mixture. The cphA gene, identified and verified in most cyanobacterial genera, directs CGP synthesis.
Two cyanophycinases depolymerize CGP. CphB acts intracellularly and CphE is secreted, and both release the dipeptide β-Asp-Arg. Because the polymer contains β-linkages rather than α-linkages, a dedicated cyanophycinase, not a general protease, is required to obtain the dipeptide. The released product retains the isopeptide linkage, so analytical methods built around standard α-linked dipeptides cannot be assumed to apply without verification. The β-Asp-Arg dipeptide can be synthesized efficiently through the simultaneous production of CGP and a CGPase, so the polymer is cleaved as it forms. The approach has been proposed for fields requiring arginine content in feed or food. Recombinant production has been established in several hosts.
| Host | Type | Status |
|---|---|---|
| Escherichia coli | Bacterium | CGP production established |
| Pseudomonas putida | Bacterium | CGP production established |
| Pseudomonas alcaligenes DIP1 | Bacterium | CGP production established |
| Nicotiana tabacum | Plant | Co-expression of CGP and CGPase recently achieved |
The plant result is the most recent. Co-expression of CGP and CGPase in Nicotiana tabacum was achieved, and the synthetic model may support sufficient storage and efficient transport of arginine and β-Asp-Arg dipeptides. For process development, the cyanophycinase route now has both microbial and plant chassis available.
The five families are not equally supported. The NRPS domain logic rests on a high-resolution structure, PDB ID: 2VSQ, and on the well documented products penicillin, bleomycin, and cyclosporine. The ATP-grasp mechanism rests on PDB ID: 2IP4 and on biochemical work with GAR synthetase, biotin carboxylase, Ddl, and glutathione synthetase. Penicillin acylase supports an entire industry around 6-APA. These three are established beyond reasonable doubt.
The AETs and the carboxypeptidase Y catalyst are different. The carboxypeptidase Y from Empedobacter brevis ATCC 14234 was reported without its amino acid sequence, coding gene sequence, or 3D crystal structure, and no confirmed follow-up has closed the gap. The AETs have no 3D structure and no published reaction mechanism. The outstanding questions are concrete: What are the catalytic residues of the AETs? How does one acylation step achieve both dipeptidyl peptidase and transferase activity with such strict specificity? What are the amino acid sequence, gene sequence, and 3D structure of the carboxypeptidase Y catalyst? Until sequences are on record, the identification of the carboxypeptidase Y catalyst cannot be independently verified.
The route to answering them is also concrete. A crystal structure of an AET, with and without an acyl donor bound, would identify the catalytic residues and the structural basis of the dual specificity. Site-directed mutagenesis of those residues would test the proposed acylation step. Sequence identification of the ATCC 14234 catalyst would settle whether carboxypeptidase Y is actually the enzyme responsible for the reported yields.
The practical reading for a researcher or process chemist is straightforward. To make 6-APA or semi-synthetic β-lactams,
Peptides referenced: Glutathione.
Related reading: Condensation Agents in SPPS: Mechanisms and Selection, Peptide Targeting Agents for In Vivo Tumor Imaging: A Practical Primer, Animal, Plant and Synthetic Peptides: Sources, Uses and Differences, Common Cosmetic Peptides: Copper, Carnosine, Glutathione, and More.